RX-3117: Phase Ib/IIa data

Data from 9 evaluable patients with relapsed or refractory metastatic pancreatic cancer in stage 1 of an open-label, U.S. Phase Ib/IIa trial showed that once-daily 700 mg oral RX-3117 given 5 times pe...